Market news

Champions Oncology Inc (CSBR) posted 9% revenue growth, 50% gross margin, and record data licensing revenue in Q1 fiscal 2027.

Motley Fool Press Release.

Moby summary of Champions Oncology, Inc.'s Q1 2027 earnings call

Champions Oncology (NASDAQ:CSBR) reported first-quarter fiscal 2027 revenue growth, improved margins and its fifth consecutive quarter of positive adjusted EBITDA, as both its translational oncology services and data licensing businesses contributed to results. Revenue for the quarter totaled $15.2

Oncology services margin improves to 51%; Adjusted EBITDA increases to $671,000HACKENSACK, NJ / ACCESS Newswire / September 10, 2026 / (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its first quarter of fiscal 2027, ended July 31, 2026.First Quarter and Recent Highlights: * Revenue of $15.

HACKENSACK, NJ / ACCESS Newswire / September 4, 2026 / (CSBR), a global leader in clinically relevant oncology research models and translational solutions, will report its financial and operational results for the quarter ended July 31, 2026, on Thursday, September 10, 2026, after market close. The company will host a conference call to discuss the results that day at 4:30 P.

New molecular imaging capabilities connect longitudinal radiopharmaceutical uptake with biodistribution, efficacy and clinically annotated PDX tumor biology in a single, U.-based workflowHACKENSACK, NJ / ACCESS Newswire / September 1, 2026 / , a leading provider of translational oncology research solutions, today announced the expansion of its integrated radiopharmaceutical development platform with new in-house SPECT/CT imaging capabilities.

Detailed price information for Champions Oncolog (CSBR-Q) from The Globe and Mail including charting and trades.

Champions Oncology Inc (CSBR) achieved record annual revenue of $59.4 million and its fourth consecutive quarter of positive adjusted EBITDA, despite a significant drop in data-license revenue.

Champions Oncology (NASDAQ:CSBR) reported record revenue for fiscal 2026 and positive adjusted EBITDA in every quarter of the year, supported by growth in its core Translational Oncology Solutions, or TOS, services business and efforts to bring radiopharmaceutical work in-house. For the fourth quar

ACCESS Newswire Press Release.

Champions Oncology and Cytek Biosciences have different growth drivers and valuations, but which life sciences stock offers better long-term upside? Let's dive in.

CSBR and CEPL have levers in place for Gross Margin improvement.

Discover why Zacks rates Champions Oncology as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore CSBR's accelerating pharmacology services and expanding data initiatives amid execution risks and commercialization timing.

HACKENSACK, NJ / ACCESS Newswire / July 20, 2026 / Champions Oncology, Inc. (NASDAQ:CSBR), a global leader in clinically relevant oncology research models and translational solutions, will report its financial and operational results for the quarter ...